临床试验/CTIS2023-503711-15-00

CTIS2023-503711-15-00招募中1 期

19873A

H. Lundbeck A/S0 个研究点目标入组 36 人开始时间: 2023年4月12日最近更新: 2024年7月22日

试验速览

阶段: 1 期
状态: 招募中
发起方: H. Lundbeck A/S
入组人数: 36

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

未提供

排除标准

未提供

研究者

发起方

H. Lundbeck A/S

相似试验

An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumours

CTIS2023-504199-19-00T3 Pharmaceuticals AG100

进行中（未招募）

APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)

CTIS2023-506975-83-00Aprogen Inc.720

进行中（未招募）

Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

CTIS2023-509210-10-00niversitair Medisch Centrum Utrecht24

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimabhead and neck squamous cell carcinoma, non-small cell lung cancer or, melanoma

CTIS2024-514034-20-00Boehringer Ingelheim International GmbH13

进行中（未招募）

Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)Metastatic cancer, Epithelial tumours

CTIS2023-503525-19-00Akamis Bio Limited220